Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD

Jessen, Frank; Block, Wolfgang; Träber, Frank; Keller, E.; Flacke, Sebastian; Papassotiropoulos, Andreas; Lamerichs, Rolf; Heun, Reinhard; Schild, H.H.

doi:10.1212/wnl.55.5.684

Cited by 157 publications

(111 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We previously showed that Cho/Cr and mI/Cr levels are also elevated in a paralimbic cortical region, the posterior cingulate gyri in aMCI [20]. Although serial MRS studies did not identify any longitudinal change in Cho, mI,, Cho/Cr or mI/Cr, levels in people with AD [1,10,18], Cho/Cr levels decreased with cholinergic agonist treatment in AD with respect to the placebo [44]. To our knowledge, no serial 1 H MRS study has been published in aMCI.…”

Section: Introductionmentioning

confidence: 93%

Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease

Kantarci¹,

Weigand²,

Petersen³

et al. 2007

Neurobiology of Aging

175

131

View full text Add to dashboard Cite

Magnetic Resonance (MR)-based volume measurements of atrophy are potential markers of disease progression in patients with amnestic mild cognitive impairment (aMCI) and Alzheimer's disease (AD). Longitudinal changes in 1 H MR spectroscopy ( 1 H MRS) metabolite markers have not been characterized in aMCI subjects. Our objective was to determine the longitudinal 1 H MRS metabolite changes in patients with aMCI, and AD, and to compare 1 H MRS metabolite ratios and ventricular volumes in tracking clinical disease progression in AD. The neuronal integrity marker Nacetylaspartate/Creatine ratio declined in aMCI and AD patients compared to cognitively normal elderly. The changein 1 H MRS metabolite ratios correlated with clinical progression about as strongly as the rate of ventricular expansion, suggesting that 1 H MRS metabolite ratios may be useful markers for the progression of AD. Choline/Creatine ratio declined in stable aMCI, compared to converter aMCI patients and cognitively normal elderly, which may be related to a compensatory mechanism in aMCI patients who did not to progress to AD.

show abstract

Section: Introductionmentioning

confidence: 93%

Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease

Kantarci¹,

Weigand²,

Petersen³

et al. 2007

Neurobiology of Aging

175

131

View full text Add to dashboard Cite

show abstract

“…AD patients have shown metabolite abnormalities like decreased NAA or NAA/Cr levels [143][144][145][146][147][148][149], elevated mI/Cr ratio [144,147], increased or decreased Cho/Cr ratio levels depending on the stage of the disease [150] and decreased Glu levels [147][148][149] in the gray matter (GM). NAA/mI ratio has been found to be useful for distinguishing between AD patients and healthy subjects.…”

Section: Magnetic Resonance Spectroscopic Imaging (Mrsi)mentioning

confidence: 99%

On the early diagnosis of Alzheimer's Disease from multimodal signals: A survey

Alberdi

Aztiria

Basarab

2016

Artificial Intelligence in Medicine

156

View full text Add to dashboard Cite

“…By utilizing MRS, reduced NAA and increased myo-inositol concentrations have been consistently found in the brain of AD patients compared to cognitively healthy elderly individuals and to be correlated to decline in cognitive performance (e.g. Chantal et al, 2002Chantal et al, , 2004Huang et al, 2001;Kantarci et al, 2004;Klunk et al, 1998;Jessen et al, 2000Jessen et al, , 2009Meyerhoff et al, 1994;Miller et al, 1993;Mohanakrishnan et al, 1997;Pfefferbaum et al, 1999a,b;Rose et al, 1999;Schuff et al, 2002;Watanabe et al, 2010). While NAA indicates loss of neuronal integrity, myo-inositol has been interpreted as a marker of gliosis (see discussion above).…”

Section: Alzheimer's Diseasementioning

confidence: 99%